Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (The Motley Fool)
What happened: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a precommercial pioneer of RNA-based therapies, continued a slide that began just ahead of the weekend. A clinical trial win that Pfizer Inc. (NYSE:PFE) announced on Thursday could mean potential competition for Alnylam’s lead candidate could be much worse than expected. In response, the stock is down 15.7% as of 11:30 a.m. EDT on Monday.
Snap Inc (NYSE:SNAP) (MarketWatch)
Snap Inc. SNAP, -7.53% shares are down 7.2% in Monday morning trading after the company confirmed in a filing late last week that it had cut 7% of its workforce. Snap said that it expected to save about $25 million in 2018 related to salaries and payroll taxes. SunTrust Robinson Humphrey analyst Youssef Squali wrote Monday that Snap’s filing “reveals more about its intent to accelerate profitability.”
Sellas Life Sciences Group Inc (NASDAQ:SLS) (Benzinga)
SELLAS Life Sciences Group, Inc. shares jumped 139.7 percent to $8.270 after the company disclosed positive interim data from its Phase 2b NeuVax trial.
Intel Corporation (NASDAQ:INTC) (CNBC)
Intel shares dropped sharply on Monday after a Bloomberg report that Apple would ditch Intel chips for an in-house model on Mac computers. Shares of Intel fell as much as 9 percent after the Bloomberg report, which cited unnamed people familiar with the matter. Apple declined to comment and Intel said it does not respond to speculations or rumors. There are many different types of chips and processors that go into Apple’s products, both from Intel and competitors like Qualcomm, Broadcom and Arm. But Apple has increasingly looked to bring design of the most important chips – for things like artificial intelligence and augmented reality – in-house, with chips for Mac, Watch, AirPods and Beats.